Suppr超能文献

丙酸氟替卡松用于慢性阻塞性肺疾病依赖呼吸机患者的短期对照试验

Controlled short-term trial of fluticasone propionate in ventilator-dependent patients with COPD.

作者信息

Nava S, Compagnoni M L

机构信息

Respiratory Intensive Care Unit, Fondazione S. Mougeri, Istituto Scientifico di Pavia, FRCCS, Pavia, Italy.

出版信息

Chest. 2000 Oct;118(4):990-9. doi: 10.1378/chest.118.4.990.

Abstract

BACKGROUND

There is no agreement about the efficacy of systemic corticosteroids in patients with COPD, but corticosteroids often are employed during exacerbations of the disease. The use of systemic or inhaled corticosteroids in patients in stable condition is even more controversial, even though the more severely affected patients seem to respond better. Unfortunately, in this subset of patients, the use of forced expiratory maneuvers frequently fails to detect significant functional response.

STUDY OBJECTIVES

We evaluated the short-term effects of an inhaled corticosteroid, fluticasone propionate (FP), on FEV(1) and on the mechanical properties of patients in stable condition with severe COPD and chronic hypercapnic respiratory failure who were receiving long-term ventilatory support. This allowed us to measure respiratory mechanics (RM) passively, thereby avoiding any problems linked with voluntary maneuvers.

DESIGN

Randomized, placebo-controlled, crossover study.

SETTING

A respiratory ICU.

PATIENTS

Twelve hypercapnic COPD patients (mean [+/- SD] PaCO(2), 60+/-11 mm Hg; mean FEV(1), 13+/-5% predicted; and mean FEV(1)/FVC, 31 +/- 7%) were enrolled.

INTERVENTIONS

A daily dose of 2,000 microg FP or placebo was administered via metered-dose inhaler during mechanical ventilation for 5 consecutive days. A washout of 72 h was allowed between regimens.

MEASUREMENTS

End-expiratory and end-inspiratory airway occlusions were performed to assess static intrinsic positive end-expiratory pressure (PEEPi,st), static compliance of the respiratory system (Cst,rs), maximal respiratory resistance (Rmax, rs), and minimal respiratory resistance (Rmin,rs). The bronchodilator response also was assessed by FEV(1) level.

RESULTS

No significant changes were found in RM after administration of the placebo. By day 6, FP had induced the following significant decreases: PEEPi,st, 4.3+/-2.4 to 3.1+/-1.7 cm H(2)O (p<0.01); Rmax,rs, 19.0+/-6.5 to 14.6+/-6 cm H(2)O/L/s (p<0.001); and Rmin,rs, 14.8+/-4.2 to 10.5+/-3.4 cm H(2)O/L/s (p<0.001). The Cst,rs and the effective additional resistance of the respiratory system did not change significantly, the latter suggesting that the major effect of FP was on the airway caliber (Rmin,rs). FEV(1) changes significantly (p<0.01) underestimated the bronchodilator response, as compared with changes in Rmin,rs.

CONCLUSIONS

We conclude that in patients in stable condition with severe COPD and chronic hypercapnic respiratory failure, a brief trial of FP may induce a bronchodilator response, mainly related to a reduction in airway resistances, that is not detected by the usual pulmonary function tests.

摘要

背景

对于慢性阻塞性肺疾病(COPD)患者使用全身糖皮质激素的疗效尚无定论,但在疾病急性加重期常使用糖皮质激素。在病情稳定的患者中使用全身或吸入糖皮质激素更具争议,尽管病情较重的患者似乎反应更好。不幸的是,在这部分患者中,用力呼气动作常常无法检测到明显的功能反应。

研究目的

我们评估了吸入糖皮质激素丙酸氟替卡松(FP)对接受长期通气支持的重度COPD和慢性高碳酸血症呼吸衰竭稳定期患者的第一秒用力呼气容积(FEV₁)及力学特性的短期影响。这使我们能够被动测量呼吸力学(RM),从而避免与自主动作相关的任何问题。

设计

随机、安慰剂对照、交叉研究。

地点

呼吸重症监护病房。

患者

纳入12例高碳酸血症COPD患者(平均[±标准差]动脉血二氧化碳分压[PaCO₂]为60±11 mmHg;平均FEV₁为预计值的13±5%;平均FEV₁/用力肺活量[FVC]为31±7%)。

干预措施

在机械通气期间,通过定量吸入器连续5天每日给予2000μg FP或安慰剂。两种治疗方案之间允许72小时的洗脱期。

测量指标

进行呼气末和吸气末气道阻断以评估静态内在呼气末正压(PEEPi,st)、呼吸系统静态顺应性(Cst,rs)、最大呼吸阻力(Rmax,rs)和最小呼吸阻力(Rmin,rs)。还通过FEV₁水平评估支气管扩张剂反应。

结果

给予安慰剂后RM无显著变化。到第6天,FP导致以下显著下降:PEEPi,st从4.3±2.4降至3.1±1.7 cmH₂O(p<0.01);Rmax,rs从19.0±6.5降至14.6±6 cmH₂O/L/s(p<0.001);Rmin,rs从14.8±4.2降至10.5±3.4 cmH₂O/L/s(p<0.001)。Cst,rs和呼吸系统的有效附加阻力无显著变化,后者表明FP的主要作用是作用于气道管径(Rmin,rs)。与Rmin,rs的变化相比,FEV₁的变化显著(p<0.01)低估了支气管扩张剂反应。

结论

我们得出结论,对于重度COPD和慢性高碳酸血症呼吸衰竭稳定期患者,短期试用FP可能会诱导支气管扩张剂反应,主要与气道阻力降低有关,而这是常规肺功能测试无法检测到的。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验